Neridronic acid for treating bone marrow lesions
View Patent ↗Oral dosage forms of osteoclast inhibitors, such as zoledronic acid, in an acid or a salt form can be used to treat or alleviate pain or related conditions, such as bone marrow lesions.
1. A method of treating a bone marrow lesion comprising:
selecting a patient having 1) a bone marrow lesion and 2) an OARSI Grade 0 or Kellgren and Lawrence Grade 0 or Grade 1 of joint space narrowing, and intravenously administering neridronic acid to the patient at least two times, for the treatment of the bone marrow lesion.
2. The method of claim 1 , wherein the neridronic acid is administered daily.
3. The method of claim 1 , wherein the neridronic acid is administered weekly.
4. The method of claim 1 , wherein the neridronic acid is administered monthly.
5. The method of claim 1 , wherein the patient is suffering from complex regional pain syndrome.
6. The method of claim 5 , wherein a fracture is an inciting event for the complex regional pain syndrome.
7. The method of claim 6 , wherein about 50 mg to about 600 mg of the neridronic acid is administered within a period of about one month.
8. The method of claim 1 , wherein administering the neridronic acid results in a reduction in size of the bone marrow lesion of at least about 20% relative to the baseline before administration of the neridronic acid.
9. The method of claim 1 , further comprising administration of a steroid.
10. The method of claim 9 , wherein about 200 mg to about 400 mg of the neridronic acid is administered within a period of about one month.
11. The method of claim 9 , wherein about 300 mg to about 600 mg of the neridronic acid is administered within a period of about one month.
12. The method of claim 10 , wherein the neridronic acid is administered in two doses.
13. The method of claim 11 , wherein the neridronic acid is administered in two doses.
14. The method of claim 1 , wherein the neridronic acid is in an acid form.
15. The method of claim 1 , wherein the neridronic acid is in a salt form.
16. A method of treating a bone marrow edema comprising: selecting a patient having 1) a bone marrow edema and 2) an OARSI Grade 0 or Kellgren and Lawrence Grade 0 or Grade 1 of joint space narrowing, and orally administering neridronic acid to the patient for the treatment of the bone marrow edema.
17. The method of claim 16 , wherein the neridronic acid is administered daily.
18. The method of claim 16 , wherein the neridronic acid is administered weekly.
19. The method of claim 16 , wherein the neridronic acid is administered monthly.
20. The method of claim 16 , wherein the patient is suffering from complex regional pain syndrome.
21. The method of claim 20 , wherein a fracture is an inciting event for the complex regional pain syndrome.
22. The method of claim 21 , wherein about 50 mg to about 600 mg of the neridronic acid is administered within a period of about one month.
23. The method of claim 16 , wherein about 200 mg to about 400 mg of the neridronic acid is administered within a period of about one month.
24. The method of claim 16 , wherein about 300 mg to about 600 mg of the neridronic acid is administered within a period of about one month.
25. The method of claim 23 , wherein the neridronic acid is administered in at least two doses.
26. The method of claim 24 , wherein the neridronic acid is administered in at least two doses.
27. The method of claim 16 , wherein the neridronic acid is in an acid form.
28. The method of claim 16 , wherein the neridronic acid is in a salt form.